Pipeline

INVERLEASE™ device

Our proprietary technology enables a unique therapeutic modality through intrathecal pseudo-delivery. This approach enhances the effectiveness of treatments for CNS conditions by allowing direct action within the central nervous system, while maximizing safety.

Unlike conventional methods, the drugs are not released into the broader system; instead, the drug-target interaction takes place inside the device, within a nano-porous capsule, minimizing systemic exposure and potential side effects.

INVERLEASE can transform how the treatments for neurodegenerative diseases are developed and applied. No other method or device can compare to it, thanks to its distinctive features:

  • EFFECTIVE – Meaningful drug-target interaction (unlike systemic modalities) enables drugs to act in the location they are needed. Drug-target interaction takes place inside the device.

  • SAFE – it is the only intrathecal delivery technology that does not release the drugs in the CSF itself, thus avoiding drug-induced immune reactions, a key limitation of CNS direct delivery of drugs.

  • CONVENIENT – Standardized implant procedures, compatible with existing technology, including percutaneous redosing, standard of care protocols and instrumentation.

NEUROSTECH is working to demonstrate device safety in humans, to unlock its full potential in multiple indications. It is particularly indicated for Neurodegenerative diseases:

  • Alzheimer Disease (AD)
  • Parkinson Disease (PD)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Frontotemporal Dementia (FTD)
  • Huntington (HD)

We have published the INVERLEASE proof of concept in a murine model of Alzheimer's disease using a miniaturized pump prototype for rodents. Anti-ß42 mAb was used to capture ß-amyloid and remove it from the CSF, resulting in 30% lower plaque formation in treated animals vs control (implanted but without the treatment).

We have completed the design and manufacturing of the human prototype which is being tested in swine models. INVERLEASE is Made of Titanium, manufactured by 3D-printing. In swine, the preclinical study was completed and the primary endpoint reached: no mAb was detected in CSF, anticipating the safety promised by the INVERLEASE modality for mAbs.

We have completed the design and manufacturing of the human prototype which is being tested in swine models. INVERLEASE is Made of Titanium, manufactured by 3D-printing. In swine, the preclinical study was completed and the primary endpoint reached: no mAb was detected in CSF, anticipating the safety promised by the INVERLEASE modality for mAbs.

Currently working on the IND-enabling swine regulatory study, focusing on the safe implantation and verify the absence of leakage of drug (antiß42 mAb) into the intrathecal space of the CNS.